Abstract
New in vivo evidence confirms that tumor-expressed Fas ligand impairs immune responses to cancer by inducing apoptosis of anti-tumor immune effector cells.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Expression of TNF-related apoptosis-inducing ligand (TRAIL) in keratinocytes mediates apoptotic cell death in allogenic T cells
Annals of Surgical Innovation and Research Open Access 19 November 2009
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
O'Connell, J., O'Sullivan, G.C., Collins, J.K. & Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184, 1075– 1082 (1996).
Cardi, G., Heaney, J.A., Schned, A.R. & Ernstoff, M.S. Expression of Fas (APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res. 58, 2078–2080 ( 1998).
Daniel, P.T. et al. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J. Immunol. 159, 3808–3815 (1997).
Hahne, M. et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363 –1366 (1996).
Bennett, M.W. and O'Connell, J. et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160, 5669–5675 ( 1998).
Khar, A., Varalakshmi, C., Pardhasaradhi, B.V.V., Mubarak Ali, A. & Kumari, A.L. Depletion of the natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing Fas ligand: a mechanism of immune evasion. Cell. Immunol. 189, 85–91 (1998).
Maeda, A., Aragane, Y. & Tezuka, T. Expression of CD95 ligand in melanocytic lesions as a diagnostic marker. Br. J. Dermatol. 139, 198–206 (1998).
Li, X.K. et al. Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid. Transplantation 66, 1416–1423 (1998).
Chen, J.-J., Sun, Y. & Nabel, G.J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282, 1714– 1717 (1998).
O'Connell, J. et al. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J. Pathol. 186, 240– 246 (1998).
Tanaka, M., Itai, T., Adachi, M. & Nagata, S. Downregulation of Fas ligand by shedding. Nature Med. 4, 31–36 (1998).
Griffith, T.S., Yu, X., Herndon, J.M., Green, D.R. & Ferguson, T.A. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5, 7–16 (1996).
O'Connell, J., Bennett, M.W., O'Sullivan, G.C., Collins, J.K. & Shanahan, F. The Fas counterattack: cancer as a site of immune privilege. Immunol. Today 20, 46–52 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
O'Connell, J., Bennett, M., O'Sullivan, G. et al. Fas counter-attack–the best form of tumor defense?. Nat Med 5, 267–268 (1999). https://doi.org/10.1038/6477
Issue Date:
DOI: https://doi.org/10.1038/6477
This article is cited by
-
Expression of TNF-related apoptosis-inducing ligand (TRAIL) in keratinocytes mediates apoptotic cell death in allogenic T cells
Annals of Surgical Innovation and Research (2009)
-
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Nature Medicine (2002)
-
Functional characterization of Fas ligand on tumor cells escaping active specific immunotherapy
Cell Death & Differentiation (2001)
-
Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
Nature Medicine (2000)
-
A cure for cancer? Dealing with minimal residual disease
Irish Journal of Medical Science (2000)
